Faculty/Author Profile

Christian A. Matarese

Dechert LLP

New York, NY, USA

Christian Matarese focuses his practice on mergers and acquisitions and various private equity transactions, and his experience includes domestic, cross-border, private and public company M&A. He also advises on venture capital and joint venture transactions and a variety of other general corporate and business matters. He represents private equity sponsors and their portfolio companies, strategic buyers and sellers and venture capital firms across various industry sectors.

In 2015, Mr. Matarese was named an “associate to watch” for nationwide private equity buyouts by Chambers USA, which noted that “he can manage a large acquisition process and make sure all aspects of a deal are taken care of." In addition, he was a key member of the team that won the LMG Life Sciences "2015 Collaboration Deal of the Year” award for work on behalf of Johnson & Johnson in connection with its strategic partnership with Google Life Sciences to innovate advanced surgical robots. Mr. Matarese was also distinguished as a New York Metro “Rising Star” by Super Lawyers in 2014 and 2015. Prior to that, he received Dechert’s Exceptional Teachers Award in recognition of his “genuine inquisitive spirit, continually seeking to expand upon his awareness and understanding of deal mechanics and market movements — inspiring others to do the same.”

Before joining Dechert, he was a corporate associate in the New York office of an international law firm.

Significant Representations

Affiliates of Centre Partners in connection with the sale of Monte Nido Holdings, LLC, a leading provider of treatment for eating disorders and exercise addiction, to Levine Leichtman Capital Partners.

Bregal Partners L.P. in connection with its investment in American Seafoods Group, LLC and its affiliates, the largest harvester of wild-caught fish for human consumption in the United States, as part of a broader deleveraging recapitalization.

Affiliates of Johnson & Johnson in connection with a strategic collaboration with Google to advance surgical robotics to benefit surgeons, patients and health care systems.

Bregal Partners L.P. on its sponsorship of Blue Harvest Fisheries, LLC and the acquisition of a fleet of Virginia-based scallop vessels and related shore assets from Peabody Corp and affiliates.

Bregal Partners L.P. on its acquisition of Shock Doctor, Inc., a leading provider of athletic performance and protective equipment, and Shock Doctor, Inc. on its business combination with McDavid, Inc.

Bregal Partners L.P. on the formation of Aqua Terra Water Management, L.P., an acquisition and organic growth platform providing water management and disposal services to onshore oilfield customers in North America, and numerous acquisitions of saltwater disposal facilities and related assets throughout the United States and Canada.

Bregal Partners L.P. on its acquisition of a leading multi-state provider of community-based residential and behavioral services as well as portfolio company add-on acquisitions, including ReMed Recovery Care Centers, LLC.

Bradford Equities Management, L.L.C. on the sale of Professional Plumbing Group, Inc. to Dunes Point Capital.

An affiliate of Quilvest Private Equity on its acquisition of National Copper & Smelting, a producer of specialty copper tubing.

One Equity Partners on its US$1.1 billion take private of MModal, Inc., a Nasdaq-quoted provider of clinical documentation services and Speech Understanding™ solutions.

Inhibitex, Inc., a clinical-stage biopharmaceutical company, on its sale to Bristol-Myers Squibb for US$2.5 billion.

Invatec S.p.A., an Italian medical device manufacturer, and its owners on their sale to Medtronic, Inc., a NYSE-listed medical technology company, in a transaction valued at up to US$500 million.

K+S A.G., a German DAX-quoted leading supplier of salt products and fertilizers on its US$1.7 billion acquisition of Morton Salt (a transaction ranked as “Highly Commended” in the Financial Times’ 2010 U.S. Innovative Lawyer Report).

Beaufour Ipsen Pharma, a French-based global biotechnology care group on its acquisition of Tercica, Inc., a Nasdaq-quoted biopharmaceutical company in a Rule 13e-3 going-private transaction valued at US$663 million.